A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck†
Article first published online: 17 SEP 2002
Copyright © 2002 American Cancer Society
Volume 95, Issue 7, pages 1472–1481, 1 October 2002
How to Cite
Tishler, R. B., Norris, C. M., Colevas, A. D., Lamb, C. C., Karp, D., Busse, P. M., Nixon, A., Frankenthaler, R., Lake-Willcutt, B., Costello, R., Case, M. and Posner, M. R. (2002), A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck. Cancer, 95: 1472–1481. doi: 10.1002/cncr.10873
Data management support was provided by Aventis and Rhône-Poulenc Rorer.
- Issue published online: 17 SEP 2002
- Article first published online: 17 SEP 2002
- Manuscript Accepted: 22 APR 2002
- Manuscript Received: 27 FEB 2002
- Aventis and Rhône-Poulenc Rorer
- 7A Phase III comparison of standard radiation therapy (RT) versus RT plus concurrent cisplatin (DDP) versus split-course RT plus concurrent DDP and 5-fluorouracil (5FU) in patients with unresectable squamous cell head and neck cancer (SCHNC): an Intergroup study [abstract]. Proc Am Soc Clin Oncol. 2000; 19: 1624., , , et al.
- 13Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy—results of a multicentric randomized German trial in advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 2001; 50: 1161–1171., , , , , , et al.
- 15A Phase I study of radiotherapy and simultaneous paclitaxel in patients with locally advanced squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol. 1996; 15: 321., , , et al.
- 29Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res. 1997; 12: 2431–2438., , , , .
- 30Radiation enhancement by taxol in squamous carcinoma of the hypopharynx (FaDu) in nude mice. Proc Am Assoc Cancer Res. 1994; 35: 674., , , , .
- 43A Radiation Therapy Oncology Group (RTOG) Phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000; 48: 7–16., , , et al.